Combination therapy before surgery for gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs before surgery for people with resectable gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-negative gastric or gastroesophageal junction cancer (Siewert type II or III) that is stage II or III and can be surgically removed.
- You have not had any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- Your organs (like blood, kidneys, liver) are working well, based on blood tests.
- You are willing to provide blood, stool, and tumor tissue samples for research.
- You do not have active autoimmune disease, uncontrolled infections, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and radiation for stomach cancer that hasn't been treated before. The goal is to see if this approach can shrink tumors and help you live longer.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This study tests a combination of two immunotherapy drugs plus chemotherapy before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of four drugs given before surgery to shrink stomach cancer and improve the chances of successful removal. It is for people with locally advanced stomach or gastroesophageal junction cancer that has not been treated yet.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.